XTL Biopharmaceuticals’ six-month loss narrows 82% to $899,000
XTLB•XTL Biopharmaceuticals’ total loss narrowed 82% year over year to $899,000 for the six months ended June 30, 2026, while general and administrative expenses rose 68% to $858,000 and revenue remained absent. Cash and cash equivalents were $1.8 million, and the company completed its acquisition of 83.4% of Psyga Bio for $3.53 million.
1. Six-month results
XTL Biopharmaceuticals’ total loss narrowed 82% year over year to $899,000 for the six months ended June 30, 2026. General and administrative expenses climbed 68% to $858,000, while revenue remained absent. Cash and cash equivalents stood at $1.8 million at June 30, 2026.
2. Psyga Bio acquisition
The company completed its acquisition of 83.4% of Psyga Bio on June 30 for total consideration of $3.53 million.




